BioCryst Pharmaceuticals, Inc.
MX ˙ BMV ˙ US09058V1035
SecurityMX:BCRX / BioCryst Pharmaceuticals, Inc.
InstitutionXponance, Inc.
Latest Disclosed Ownership21,137 shares
Latest Disclosed Value $ 201,224
Xponance, Inc. reports 5.04% decrease in ownership of BCRX / BioCryst Pharmaceuticals, Inc.

On May 13, 2026 - Xponance, Inc. filed a 13F-HR form disclosing ownership of 21,137 shares of BioCryst Pharmaceuticals, Inc. (MX:BCRX) valued at $201,224 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 22,258 shares of BioCryst Pharmaceuticals, Inc.. This represents a change in shares of -5.04% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F BIOCRYST PHARMACEUTICALS COM 09058V103 21,137 -1,121 -5.04 201 16.18 0.0014
2026-02-12 2025-12-31 13F BIOCRYST PHARMACEUTICALS COM 09058V103 22,258 94 0.42 174 2.98 0.0013
2025-11-12 2025-09-30 13F BIOCRYST PHARMACEUTICALS COM 09058V103 22,164 248 1.13 168 -14.29 0.0013
2025-08-14 2025-06-30 13F BIOCRYST PHARMACEUTICALS COM 09058V103 21,916 6,349 40.78 196 68.97 0.0016
2025-05-01 2025-03-31 13F BIOCRYST PHARMACEUTICALS COM 09058V103 15,567 671 4.50 117 3.57 0.0011
2025-02-11 2024-12-31 13F BIOCRYST PHARMACEUTICALS COM 09058V103 14,896 1,242 9.10 112 8.74 0.0010
2024-11-12 2024-09-30 13F BIOCRYST PHARMACEUTICALS COM 09058V103 13,654 674 5.19 104 28.75 0.0010
2024-08-14 2024-06-30 13F BIOCRYST PHARMACEUTICALS COM 09058V103 12,980 1,505 13.12 80 37.93 0.0008
2024-05-13 2024-03-31 13F BIOCRYST PHARMACEUTICALS COM 09058V103 11,475 94 0.83 58 -14.71 0.0006
2024-01-31 2023-12-31 13F BIOCRYST PHARMACEUTICALS COM 09058V103 11,381 182 1.63 68 -13.92 0.0008
2023-10-24 2023-09-30 13F BIOCRYST PHARMACEUTICALS COM 09058V103 11,199 105 0.95 79 1.28 0.0011
2023-07-14 2023-06-30 13F BIOCRYST PHARMACEUTICALS COM 09058V103 11,094 487 4.59 78 -11.36 0.0010
2023-04-18 2023-03-31 13F BIOCRYST PHARMACEUTICALS COM 09058V103 10,607 0 0.00 88 -27.27 0.0013
2023-01-24 2022-12-31 13F BIOCRYST PHARMACEUTICALS COM 09058V103 10,607 163 1.56 122 -8.33 0.0020
2022-10-24 2022-09-30 13F BIOCRYST PHARMACEUTICALS COM 09058V103 10,444 370 3.67 132 23.36 0.0025
2022-08-02 2022-06-30 13F BIOCRYST PHARMACEUTICALS COM 09058V103 10,074 10,074 107 0.0021
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.